Allgeier H1 FY26 EBIT falls 10.87% to EUR 4.1 million; revenue rises 10% to EUR 162 million
Reuters2026/08/06 17:16- Allgeier revenue rose 10% to EUR 162 million in the first half of 2026.
- Reported EBITDA edged down to EUR 14.9 million, while adjusted EBITDA increased to EUR 17.6 million.
- EBIT slipped to EUR 4.1 million, while profit before tax rose to EUR 1.2 million.
- Net debt increased to EUR 74 million as interest-bearing financial debt climbed to EUR 95 million; cash fell to EUR 35 million.
- Guidance reiterated for continuing operations: revenue of EUR 335 million-EUR 375 million, adjusted EBITDA of EUR 46 million-EUR 52 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.
Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.
Fogo Foundation Attacked, Approximately 400 Million FOGO Tokens Transferred
Blue Owl (OWL.US) teams up with PIMCO to tailor a $2.4 billion GPU financing for IREN (IREN.US)
A $2.4 billions debt financing round, led by funds under Blue Owl Capital Inc., has been finalized. The funds will be allocated to cloud service provider IREN Ltd. to purchase NVIDIA's Blackwell Ultra GPUs, supporting the development of its data center campus in Canada.
Crypto prices
More
